Your browser doesn't support javascript.
loading
Vaccination to Reduce Antimicrobial Resistance Burden-Data Gaps and Future Research.
Tadesse, Birkneh Tilahun; Keddy, Karen H; Rickett, Natasha Y; Zhusupbekova, Aidai; Poudyal, Nimesh; Lawley, Trevor; Osman, Majdi; Dougan, Gordon; Kim, Jerome H; Lee, Jung-Seok; Jeon, Hyon Jin; Marks, Florian.
Afiliação
  • Tadesse BT; International Vaccine Institute, Seoul, Republic of Korea.
  • Keddy KH; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Rickett NY; Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
  • Zhusupbekova A; Independent Consultant, Johannesburg, South Africa.
  • Poudyal N; International Vaccine Institute, Seoul, Republic of Korea.
  • Lawley T; International Vaccine Institute, Seoul, Republic of Korea.
  • Osman M; International Vaccine Institute, Seoul, Republic of Korea.
  • Dougan G; Wellcome Sanger Institute and Microbiotica, Cambridge, United Kingdom.
  • Kim JH; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
  • Lee JS; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom.
  • Jeon HJ; International Vaccine Institute, Seoul, Republic of Korea.
  • Marks F; Seoul National University, College of Natural Sciences, Seoul, Republic of Korea.
Clin Infect Dis ; 77(Suppl 7): S597-S607, 2023 12 20.
Article em En | MEDLINE | ID: mdl-38118013
ABSTRACT
Antimicrobial resistance (AMR) poses an immediate danger to global health. If unaddressed, the current upsurge in AMR threatens to reverse the achievements in reducing the infectious disease-associated mortality and morbidity associated with antimicrobial treatment. Consequently, there is an urgent need for strategies to prevent or slow the progress of AMR. Vaccines potentially contribute both directly and indirectly to combating AMR. Modeling studies have indicated significant gains from vaccination in reducing AMR burdens for specific pathogens, reducing mortality/morbidity, and economic loss. However, quantifying the real impact of vaccines in these reductions is challenging because many of the study designs used to evaluate the contribution of vaccination programs are affected by significant background confounding, and potential selection and information bias. Here, we discuss challenges in assessing vaccine impact to reduce AMR burdens and suggest potential approaches for vaccine impact evaluation nested in vaccine trials.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / Antibacterianos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / Antibacterianos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article